Related Experiment Video
Updated: Aug 7, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
DNA Sensing Pathways in Innate Immunity: Implications for Alzheimer's Disease Progression and Therapy
Chenmo Shi1, Ye Liu2, Yanli Zhu3
1Center for Rehabilitation Medicine, Department of Rehabilitation Medicine, Rehabilitation & Sports Medicine Research Institute of Zhejiang Province, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Molecular Neurobiology
|August 5, 2026
Summary
DNA sensors contribute to Alzheimer's disease (AD) by triggering neuroinflammation. Targeting these sensors, like cGAS-STING and AIM2, offers potential therapeutic strategies for AD.
Area of Science:
- Neuroimmunology
- Molecular Biology
- Genetics
Background:
- DNA sensors are crucial for innate immunity, detecting both microbial and self-DNA.
- Aberrant DNA sensor activation in Alzheimer's disease (AD) promotes neuroinflammation via pathways like type I interferon (IFN-I) signaling.
- This neuroinflammation contributes to AD hallmarks including amyloid pathology, tau-related inflammation, and cognitive decline.
Purpose of the Study:
- To review the role of DNA sensors in Alzheimer's disease pathogenesis.
- To summarize evidence linking specific DNA sensors (cGAS-STING, AIM2, TLR9) to AD.
- To evaluate therapeutic strategies and translational challenges for targeting DNA-sensing pathways in AD.
Main Methods:
- Literature review of current evidence on DNA sensors and AD.
- Emphasis on cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) and absent in melanoma 2 (AIM2) pathways.
- Discussion of toll-like receptor 9 (TLR9) roles and emerging DNA sensors.
Main Results:
- Strong evidence links cGAS-STING and AIM2 pathways to AD pathogenesis.
- TLR9 plays context-dependent roles in AD.
- Dysfunctional DNA sensing amplifies neuroinflammation, exacerbating AD pathology.
Conclusions:
- DNA sensors are key players in AD-associated neuroinflammation and pathology.
- Targeting DNA-sensing pathways, particularly cGAS-STING and AIM2, presents therapeutic opportunities for AD.
- Challenges in therapeutic translation include BBB penetration and disease-stage specificity.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...